Cite
HARVARD Citation
Reid, T. et al. (n.d.). Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet oncology. 16 (9), pp. 1133-1142. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reid, T. et al. (n.d.). Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet oncology. 16 (9), pp. 1133-1142. [Online].